###begin article-title 0
MHC Haplotype Matching for Unrelated Hematopoietic Cell Transplantation
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 141 146 <span type="species:ncbi:9606">human</span>
Current criteria for the selection of unrelated donors for hematopoietic cell transplantation (HCT) include matching for the alleles of each human leukocyte antigen (HLA) locus within the major histocompatibility complex (MHC). Graft-versus-host disease (GVHD), however, remains a significant and potentially life-threatening complication even after HLA-identical unrelated HCT. The MHC harbors more than 400 genes, but the total number of transplantation antigens is unknown. Genes that influence transplantation outcome could be identified by using linkage disequilibrium (LD)-mapping approaches, if the extended MHC haplotypes of the unrelated donor and recipient could be defined.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 110 120 110 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B,</italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
###xml 171 198 171 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -C, -DRB1, -DQB1</italic>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
We isolated DNA strands extending across 2 million base pairs of the MHC to determine the physical linkage of HLA-A, -B, and -DRB1 alleles in 246 HCT recipients and their HLA-A, -B, -C, -DRB1, -DQB1 allele-matched unrelated donors. MHC haplotype mismatching was associated with a statistically significantly increased risk of severe acute GVHD (odds ratio 4.51; 95% confidence interval [CI], 2.34-8.70, p < 0.0001) and with lower risk of disease recurrence (hazard ratio 0.45; 95% CI, 0.22-0.92, p = 0.03).
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 89 105 89 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
The MHC harbors genes that encode unidentified transplantation antigens. The three-locus HLA-A, -B, -DRB1 haplotype serves as a proxy for GVHD risk among HLA-identical transplant recipients. The phasing method provides an approach for mapping novel MHC-linked transplantation determinants and a means to decrease GVHD-related morbidity after HCT from unrelated donors.
###end p 6
###begin p 7
A novel method of MHC haplotype matching provides a means to decrease graft-versus-host disease-related morbidity after transplantation from unrelated donors.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 519 525 <span type="species:ncbi:9606">people</span>
###xml 789 794 <span type="species:ncbi:9606">human</span>
###xml 1045 1050 <span type="species:ncbi:9606">human</span>
Graft rejection and graft-versus-host disease (GVHD) are feared complications of hematopoietic cell transplantation (HCT). GVHD can affect all parts of the body, and, if severe (grade III to IV out of a scale of IV), can lead to the death of the transplant recipient. GVHD or rejection of the graft occurs when there are differences in specific proteins involved in the immune response (known as HLA antigens) between donor and recipient that stimulate the immune reaction. GVHD and graft rejection occur most often in people who receive transplants from unrelated donors because, although when donors are matched to recipients matching is done for the most important HLA antigens known to be involved, it has not technically been possible to match for all possible antigens. However, the human genome is organized into segments or blocks of closely linked genetic variants that are inherited as "haplotypes" on the same DNA strand of a chromosome. Most of the genes that code for HLA antigens are physically located together in one part of the human genome, known as the MHC region. Currently three HLA markers from this region (HLA-A, -B, -DRB1) are matched when matching donors and recipients. If it were possible to better map the structure of this region, it would be possible to better match recipients and donors (especially unrelated donors) for the unidentified transplantation antigens and reduce the chance of recipients getting GVHD or rejecting their grafts.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 228 240 228 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, B, DR</italic>
Current strategies to define MHC haplotype blocks look at, on average, a length of only 18,000 base pairs and hence cannot define extended MHC haplotypes. Previously, this group of researchers developed a method of defining the HLA-A, B, DR haplotypes in recipients and their HLA-matched unrelated transplant donors using high-quality DNA containing 2 million base pairs across the MHC region. They wanted see if using this technique might provide a way to better assess the risk recipients have of developing GVHD or of having recurrent disease.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 464 471 <span type="species:ncbi:9606">patient</span>
They studied 246 HCT recipients and their donors who had been matched for HLA-A, -B, -C, -DRB1, -DQB1 by current techniques. The recipients were having HCT for a variety of hematological cancers: acute lymphoid leukemia, acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndrome. They found that, using the new technique, 22% of the donor-recipient pairs were haplotype-mismatched. Taking various other factors into account, including age, and patient and donor gender, MHC haplotype mismatching was associated with an approximately four times greater risk of severe acute GVHD but with a lower risk of disease recurrence. The lower risk of recurrence is believed to be because transplanted cells do not only replace abnormal cancerous cells but also react against them and therefore decrease the chance of the cancer recurring; mismatched cells are known to be more stimulated to react against the cancerous cells.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
The results here suggest that this new haplotype matching method can provide a way to assess the risk of GVHD after HCT from unrelated donors, and in future could be considered as a technique to match donors and recipients.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
*  has a page of information on stem cell transplantation, including HCT
###end p 19
###begin p 20
*  holds one of the largest databases of unrelated donors in the world
###end p 20
###begin p 21
* The  has a page of questions and answers on HCT
###end p 21
###begin p 22
* The  describes outcomes research in transplantation
###end p 22
###begin p 23
* The  describes how HLA-typed unrelated donors are identified
###end p 23
###begin p 24
* The  is involved in facilitating stem cell donation across international boundaries
###end p 24
###begin title 25
Introduction
###end title 25
###begin p 26
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b001">1</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b002">2</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b003">3</xref>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b004">4</xref>
###xml 621 622 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b005">5</xref>
###xml 704 705 704 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b006">6</xref>
###xml 800 801 800 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b007">7</xref>
###xml 802 803 802 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b008">8</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b009">9</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b012">12</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
A hallmark of the human genome is its organization into segments or blocks of closely linked genetic variants that are inherited as haplotypes on the same DNA strand of a chromosome [1,2]. Genes that cause disease are located within haplotypes, and they can be identified by testing the association of disease with informative single nucleotide polymorphisms (SNPs) and other genomic markers [3]. Intense efforts are in progress to define the linkage of SNPs in genomic DNA, to specify the organization of SNPs into haplotype blocks, and to identify the SNPs that could serve as proxies for haplotype blocks (tagSNPs) [4,5]. This information provides powerful tools for mapping genes that cause disease [6]. When family studies are not available, haplotypes can be inferred with statistical methods [7,8]. Because haplotypes define not one, but many, physically linked markers, they provide important information regarding traits or diseases resulting from the additive effects of genetic variation that may alter disease susceptibility or severity and response to therapy [9-12].
###end p 26
###begin p 27
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b013">13</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b019">19</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b013">13</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b019">19</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b021">21</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b022">22</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b026">26</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b027">27</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b028">28</xref>
###xml 1143 1145 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b028">28</xref>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b030">30</xref>
###xml 1487 1489 1487 1489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b028">28</xref>
###xml 1490 1492 1490 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b030">30</xref>
###xml 1617 1619 1617 1619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b031">31</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 159 164 <span type="species:ncbi:9606">human</span>
Haplotypes of the human major histocompatibility complex (MHC) can be defined by using human leukocyte antigen (HLA) alleles as highly polymorphic markers. In human populations, multiple blocks of genetic variation in the MHC are strongly associated with each other as extended haplotypes [13-19]. Haplotypes that share the same HLA alleles may also share discrete segments or blocks of highly conserved sequences in strong positive LD with those HLA alleles [13,19-21]. HLA haplotypes serve as a model system for studies of disease association [22-26], but their biological implications have not been defined for solid organ and hematopoietic cell transplantation (HCT) [27,28]. In HCT, differences between polymorphic HLA antigens of the donor and recipient stimulate alloimmune reactions that cause graft-versus-host disease (GVHD) or graft rejection. HLA genotypically identical siblings are preferred as donors because the inheritance of identical MHC haplotypes by descent includes identity for all variation within the two parental MHC haplotypes. HLA-matched unrelated donors can be used for HCT when a related donor is not available [28-30]. The identification of HLA-matched unrelated donors is feasible because matching for two HLA loci will often determine matching for the third, a consequence of a phenomenon known as linkage disequilibrium (LD). HLA-allele matching has been used as a surrogate for MHC haplotype matching in an effort to reduce risks after unrelated HCT [28-30]. Nevertheless, GVHD remains a significant and potentially life-threatening complication after HLA-identical unrelated HCT [31].
###end p 27
###begin p 28
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b014">14</xref>
###xml 747 759 747 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, B, DR</italic>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b032">32</xref>
Many of the more than 400 genes within the 7.6-million-base pair MHC region have immune-related functions, but the total number of transplantation antigens encoded within the MHC remains unknown. The dense clustering and strong LD of genes within the MHC could provide a framework for mapping genes that cause GVHD, if the extended MHC haplotypes of the unrelated donor and recipient could be defined. Current mapping strategies using selected tagSNPs to define MHC haplotype blocks that average 18,000 base pairs in length are not sufficient to define extended MHC haplotypes [14]. To overcome this limitation, we isolated DNA strands extending across 2 million base pairs of the MHC containing numerous haplotype blocks, and we then defined the HLA-A, B, DR haplotypes in recipients and their HLA-matched unrelated transplant donors [32]. The risks of post-transplant complications associated with haplotype mismatching were measured.
###end p 28
###begin title 29
Methods
###end title 29
###begin title 30
###xml 6 18 <span type="species:ncbi:9606">Participants</span>
Study Participants
###end title 30
###begin p 31
###xml 168 195 168 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -C, -DRB1, -DQB1</italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 468 473 468 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 477 485 477 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 617 618 617 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 640 645 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 647 648 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 662 667 662 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
###xml 711 712 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
###xml 987 995 <span type="species:ncbi:9606">patients</span>
Patients were eligible (a) if they received a myeloablative conditioning regimen and T cell-replete HCT with bone marrow or growth-factor-mobilized blood cells from an HLA-A, -B, -C, -DRB1, -DQB1 allele-identical unrelated donor for treatment of a blood disorder, and cyclosporine and methotrexate for post-grafting immunosuppression; (b) if lymphoblastoid cell lines were available from both the donor and recipient; and (c) if they were heterozygous at HLA-B and at HLA-A or HLA-DRB1. 246 patients met all three study criteria. 42 other patients were excluded because they were homozygous at two or all three loci (n = 22), homozygous at HLA-B (n = 5), or the HLA-A and -DRB1 allele genotyping was ambiguous (n = 15); haplotyping of these pairs will be feasible in the future when the method is developed to include additional polymorphic loci. The institutional review board of the Fred Hutchinson Cancer Research Center approved the study, and informed consent was obtained from all patients.
###end p 31
###begin title 32
Donor HLA Selection Criteria
###end title 32
###begin p 33
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b033">33</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b034">34</xref>
###xml 167 194 167 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -C, -DRB1, -DQB1</italic>
###xml 228 236 228 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DPB1</italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b033">33</xref>
HLA-compatible unrelated donors were selected as previously described [33,34]. In the present study, retrospective sequencing was performed to confirm donor-recipient HLA-A, -B, -C, -DRB1, -DQB1 allele identity and to determine HLA-DPB1 alleles in 226 transplant pairs [33].
###end p 33
###begin title 34
###xml 36 46 36 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B,</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
Haplotyping to Determine Linkage of HLA-A, -B, and -DRB1 Alleles
###end title 34
###begin p 35
###xml 91 101 91 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B,</italic>
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b032">32</xref>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 403 408 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 743 753 743 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B,</italic>
###xml 758 763 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
###xml 890 900 890 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B,</italic>
###xml 904 909 904 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
###xml 951 959 951 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040008-g001">Figure 1</xref>
###xml 1188 1190 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b032">32</xref>
###xml 1268 1281 1268 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-C, -DQB1,</italic>
###xml 1285 1290 1285 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DPB1</italic>
We previously described a novel DNA microarray method to determine the physical linkage of HLA-A, -B, and -DRB1 alleles when family study is not available [32]. Genomic DNA was extracted from lymphoblastoid cell lines under conditions that minimize shearing and then hybridized to arrays containing two oligonucleotide probes, each specific for the two HLA-B alleles in the sample. The linked HLA-A and -DRB1 alleles on the captured HLA-B allele-specific strands were then genotyped by using oligonucleotide probes. Relative probe hybridization signal intensities were quantified with the aid of software dedicated to a fluorescence scanner and used to assign recipient and donor haplotypes. A pair was defined as MHC haplotype-matched if the HLA-A, -B, and -DRB1 alleles were physically linked to each other on the captured haplotype; a pair was defined as MHC haplotype-mismatched if the HLA-A, -B, or -DRB1 alleles were in any other rearrangement (Figure 1). The laboratory information was interpreted without knowledge of clinical outcomes and vice versa. In all cases, MHC haplotypes assigned by laboratory methods were concordant with those deduced from informative family studies [32]. In the present study, phase determination did not include consideration of HLA-C, -DQB1, or -DPB1 loci. Analysis of these genes will be feasible with future modifications of the haplotyping method.
###end p 35
###begin title 36
Transplantation Procedure
###end title 36
###begin p 37
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b034">34</xref>
###xml 101 108 101 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040008-t001">Table 1</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b034">34</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b033">33</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 1506 1514 <span type="species:ncbi:9606">patients</span>
Patients were prepared for transplantation with the use of myeloablative conditioning regimens [34] (Table 1). Pre-transplant disease risk was categorized as low-, intermediate-, or high-risk according to established criteria [34]. GVHD and recurrent malignancy were assessed as previously described [33]. In summary, conventional grading of acute GVHD incorporates the presence of the disease and its peak severity, which is related to the efficacy of treatment. Grade 0 indicates that the prophylactic immunosuppressive regimen administered after the transplant was sufficient to prevent clinical manifestations of GVHD. Grades I, II, III, and IV indicate that the immunosuppressive regimen was not sufficient to prevent clinical manifestations, and higher grades indicate increasing peak severity. Grade I GVHD indicates that manifestations were limited to the skin with less than 50% body surface involvement, and in most cases, the GVHD resolved spontaneously. Grade II GVHD indicates limited involvement of the gastrointestinal tract or liver, or more severe involvement of the skin, and in most cases, additional immunosuppressive treatment was sufficient to control disease. Grade III GVHD indicates more severe involvement of the gastrointestinal tract or liver, and in many cases, additional treatment did not readily control the disease. Grade IV GVHD indicates that GVHD was a major contributing cause of death. Transplant-related mortality and overall mortality are significantly higher among patients with grades III or IV acute GVHD compared to those with grades 0, I, or II GVHD. For these reasons, grades III-IV GVHD has been used as clinically meaningful endpoint in association analyses.
###end p 37
###begin title 38
Statistical Analyses
###end title 38
###begin p 39
###xml 514 522 514 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DPB1</italic>
###xml 1099 1101 1099 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 342 349 <span type="species:ncbi:9606">patient</span>
###xml 399 406 <span type="species:ncbi:9606">patient</span>
###xml 443 450 <span type="species:ncbi:9606">patient</span>
We used logistic regression to evaluate the association of MHC haplotype mismatching with grades III-IV acute GVHD. Cox regression was used to compare the hazards of recurrent malignancy, chronic GVHD, mortality, and transplant-related mortality. In addition to haplotype matching, all regression models contained variables for disease risk, patient age at transplantation, year of transplantation, patient/donor gender (female donor for male patient versus all other combinations), and presence of mismatching at HLA-DPB1. A test for interaction between number of common haplotypes and haplotype mismatching was performed by including the term "number x mismatch" in the regression model for GVHD, where "number" represents the number of common haplotypes modeled as a continuous linear variable, and "mismatch" is an indicator variable for haplotype mismatching. This amounted to testing if there was a linear increase (or decrease) in the odds ratios (ORs) of acute GVHD for haplotype mismatching compared to haplotype matching as the number of common haplotypes ranged from 0 to 2. All reported p-values are two-sided and were estimated from the Wald test, with no adjustments for multiple comparisons. Estimates of overall survival were calculated using the Kaplan-Meier method, and cumulative incidence estimates were used to summarize the probabilities of recurrent malignancy and transplant-related mortality. Death without recurrent malignancy was considered a competing risk for recurrent malignancy, and recurrent malignancy was considered a competing risk for transplant-related mortality.
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
HLA-A, -B, -DRB1 Linkage
###end title 41
###begin p 42
###xml 15 42 15 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -C, -DRB1, -DQB1</italic>
###xml 100 107 100 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040008-t001">Table 1</xref>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 289 290 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 317 325 317 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 348 353 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 373 377 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 379 380 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 571 579 571 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040008-st001">Table S1</xref>
A total of 246 HLA-A, -B, -C, -DRB1, -DQB1 allele-matched transplants were evaluated in this study (Table 1). Of the 246 donor-recipient pairs, 191 (78%) were haplotype-matched and 55 (22%) were haplotype-mismatched. The haplotype-mismatched pairs differed in linkage from HLA-B to HLA-A (n = 18; 33%), from HLA-B to HLA-DRB1 (n = 34; 62%) or from HLA-B to both HLA-A and -DRB1 (n = 3; 6%). Recipients had a total of 262 different haplotypes, 197 of which were identified only once. Donors had a total of 299 different haplotypes, 239 of which were identified only once (Table S1).
###end p 42
###begin title 43
GVHD
###end title 43
###begin p 44
###xml 473 481 473 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040008-g002">Figure 2</xref>
###xml 891 896 891 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 900 905 900 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 955 960 955 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 964 972 964 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
Of the 246 patients in this study, two could not be evaluated for acute GVHD. One died on day 8 with multi-organ failure, and the other had recurrent malignancy without evidence of GVHD on day 19. Among the 244 patients who could be evaluated, the overall probability of grades III-IV acute GVHD was 34.8%. The probability of grades III-IV acute GVHD was 26.5% (2.6% grade IV) among haplotype-matched patients and 63.6% (3.6% grade IV) among haplotype-mismatched patients (Figure 2A). The percentages of haplotype-matched patients developing grade 0, I, II, III, and IV acute GVHD were 9.0, 4.0, 60.8, 23.8, and 2.6, respectively. Among haplotype-mismatched patients, the percentages developing grades 0, I, II, III, and IV were 3.6, 1.8, 30.9, 60.0, and 3.6, respectively. The probability of grades III-IV acute GVHD was 61% among haplotype-mismatched patients who differed in linkage from HLA-B to HLA-A and 62% among those who differed in linkage from HLA-B to HLA-DRB1.
###end p 44
###begin p 45
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 401 409 401 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DPB1</italic>
###xml 437 445 437 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DPB1</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
The unadjusted OR for grades III-IV acute GVHD was 4.87 (95% confidence interval [CI], 2.57-9.20, p < 0.0001) for haplotype-mismatched patients compared to haplotype-matched patients. After adjusting for the factors described above, the OR of grades III-IV acute GVHD was 4.51 (95% CI, 2.34-8.70, p < 0.0001). The odds of GVHD conferred by haplotype mismatching were similar among patients matched at HLA-DPB1 and patients mismatched at HLA-DPB1 (ORs of 5.08 and 4.79, respectively).
###end p 45
###begin p 46
###xml 83 92 83 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, B,</italic>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b013">13</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b018">18</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b020">20</xref>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 737 745 <span type="species:ncbi:9606">patients</span>
###xml 1031 1039 <span type="species:ncbi:9606">patients</span>
The strong positive LD across the MHC that accounts for the association of certain HLA-A, B, and DRB1 alleles on extended HLA haplotypes is not limited to common HLA alleles [13,18,20]. To determine whether the rate of haplotype matching is related to the presence of common haplotypes, we determined the haplotype match rate among patients with 0, 1, or 2 common haplotypes. Among the 246 patients, 229 (93%) were of Northern European descent and 17 (7%) were self-designated African, Asian, Hispanic, Native American, or other racial groups. Statistically inferred haplotypes occurring at a 0.2% or greater frequency in an unrelated donor population () were used to group the patients by the number of common haplotypes. Among the 229 patients of Northern European descent, 45 (19%) had no common haplotype, 130 (57%) had one, and 54 (24%) had two. For these three groups, the proportion of haplotype-matched donor-recipient pairs was 33/45 (73%), 102/130 (78%), and 42/54 (78%), respectively. Among the 17 non-Northern European patients, the proportion of haplotype-matched pairs was 3/6, 10/10, and 1/1, respectively.
###end p 46
###begin p 47
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b013">13</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b019">19</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b021">21</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b022">22</xref>
###xml 694 701 694 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040008-t002">Table 2</xref>
###xml 820 821 820 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Previous studies have described the presence of highly conserved regions between common HLA haplotypes that share the same HLA alleles [13,19,21,22]. Since haplotype mismatched pairs share certain HLA alleles and differ for others, the effect of haplotype mismatching could differ depending on the degree to which the mismatching haplotypes share conserved regions within the MHC. To address this question, we examined the association between haplotype mismatching and the probability of GVHD according to the number of common haplotypes. Among all donor-recipient pairs in the study, the magnitude of the effect of haplotype mismatching increased as the number of common haplotypes increased (Table 2), although the ORs were not statistically significantly different among the groups with 0, 1, or 2 common haplotypes (p = 0.20).
###end p 47
###begin p 48
###xml 254 262 <span type="species:ncbi:9606">patients</span>
A total of 42 donor-recipient pairs were homozygous at two or more loci, and could not be tested by our method. Of these 42 transplants, 12 (28.6%) developed grades III-IV acute GVHD, an incidence similar to that observed among the 189 haplotype-matched patients (26.5%).
###end p 48
###begin p 49
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
Compared to haplotype-matched patients, haplotype-mismatched patients had an unadjusted hazard ratio (HR) of 1.03 for chronic GVHD (95% CI, 0.69-1.52, p = 0.90) and an adjusted HR of 1.05 (95% CI, 0.72-1.55, p = 0.79). 14% of haplotype-matched patients who developed grades III-IV acute GVHD died before day 100, compared to 11% among haplotype-mismatched patients.
###end p 49
###begin title 50
Recurrent Malignancy and Mortality
###end title 50
###begin p 51
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 252 260 252 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040008-g002">Figure 2</xref>
###xml 263 270 263 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040008-t003">Table 3</xref>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
The increased risk of grades III-IV acute GVHD was accompanied by a statistically significantly decreased hazard of recurrent malignancy among haplotype-mismatched patients compared to haplotype-matched patients (HR 0.45; 95% CI, 0.22-0.92, p = 0.03) (Figure 2B; Table 3).
###end p 51
###begin p 52
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 200 208 200 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040008-g002">Figure 2</xref>
###xml 211 218 211 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040008-t003">Table 3</xref>
###xml 910 918 910 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040008-g002">Figure 2</xref>
###xml 984 985 984 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 531 539 <span type="species:ncbi:9606">patients</span>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
###xml 827 835 <span type="species:ncbi:9606">patients</span>
There was a suggestion of increased risk of transplant-related mortality with MHC haplotype mismatching, but this association was not statistically significant (HR 1.44; 95% CI, 0.86-2.40, p = 0.17) (Figure 2C; Table 3). Twenty-six of 45 (58%) haplotype-matched patients with grade III acute GVHD died (19 of the 26 deaths from transplant-related causes), and 15 of 33 (45%) haplotype-mismatched patients with grade III acute GVHD died (14 of the 15 deaths from transplant-related causes). Thirty-one of 50 (62%) haplotype-matched patients with grades III-IV acute GVHD died (24 deaths without prior disease recurrence), compared to 17 of 35 (49%) haplotype-mismatched patients (16 deaths without prior disease recurrence). The decrease in recurrent malignancy among haplotype-mismatched patients compared to haplotype-matched patients coupled with the increase in severe GVHD led to similar overall survival (Figure 2D) and adjusted hazards of mortality (HR 0.95; 95% CI, 0.62-1.47, p = 0.83).
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b028">28</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b030">30</xref>
###xml 938 939 938 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b005">5</xref>
###xml 940 942 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b014">14</xref>
###xml 943 945 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b015">15</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b019">19</xref>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b026">26</xref>
###xml 1238 1239 1238 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b002">2</xref>
###xml 1240 1241 1240 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b003">3</xref>
###xml 1242 1243 1242 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b006">6</xref>
In this study of HLA-matched transplant recipients and donors, haplotype mismatching was associated with a statistically significantly increased risk of severe acute GVHD. These results indicate that the HLA haplotype can serve as a proxy for GVHD risk. The advent of the polymerase chain reaction (PCR) assay in the 1980s ushered in the HLA molecular typing era and provides the basis for current criteria for donor selection in support of unrelated HCT (; ). Although locus-by-locus matching of donor and recipient HLA alleles can reduce risks of graft failure and GVHD [28-30], HLA-identical transplant recipients still suffer from potentially life-threatening GVHD. Since HLA-matched unrelated donors and recipients are not identical by descent, we hypothesized that some donor-recipient pairs have identical MHC haplotypes of physically linked HLA alleles, while others have different haplotypes. Given the strong LD across the MHC [5,14,15,19,26], MHC haplotype matching may predict similarity for the more than 400 immune-related MHC-resident genes that could cause GVHD. Since it would not be feasible to assess each MHC polymorphism individually, we applied classical concepts of LD mapping to measure haplotype-associated risk [2,3,6].
###end p 54
###begin p 55
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b035">35</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b024">24</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b036">36</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b037">37</xref>
###xml 642 663 642 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -C, -DRB1,</italic>
###xml 668 673 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DQB1</italic>
###xml 891 900 891 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DPB1,</italic>
###xml 917 925 917 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DPB1</italic>
###xml 608 616 <span type="species:ncbi:9606">patients</span>
###xml 856 864 <span type="species:ncbi:9606">patients</span>
Family studies are not available for unrelated transplant donors. Population statistics for individual haplotype inference may be inaccurate [35], and previously available laboratory techniques could not be used to define haplotypes across large distances within the MHC [24,36]. Application of our new method uncovered haplotype mismatching in 20% of HLA allele-matched unrelated pairs. The increment in GVHD risk associated with haplotype mismatching was at least comparable in magnitude, if not greater than the increment associated with a single HLA mismatch among related HCT recipients [37]. Since the patients and donors had identical HLA-A, -B, -C, -DRB1, and -DQB1 alleles, GVHD could not have been caused by disparity for these classical HLA genes. Furthermore, the magnitude of the effect associated with haplotype mismatching was similar among patients matched and mismatched at HLA-DPB1, indicating that HLA-DPB1 cannot explain the association of haplotype mismatching with GVHD. These results support the concept that the MHC harbors additional genes that encode transplantation antigens. Morbidity from GVHD after HCT might be lowered not only by matching the individual HLA alleles of the donor and recipient, but also by matching their extended MHC haplotypes.
###end p 55
###begin p 56
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b038">38</xref>
###xml 564 574 564 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A*0201</italic>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b039">39</xref>
###xml 607 617 607 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A*0201</italic>
###xml 986 991 986 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 996 998 996 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-C</italic>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b040">40</xref>
###xml 1114 1119 1114 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 1124 1126 1124 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-C</italic>
The current study was not designed to examine any of the many genes outside the MHC that could cause GVHD [38]. Since these genes are not HLA linked, it is unlikely that they could have affected the association between MHC haplotype mismatching and risk of GVHD observed in the current study. Included among the many potential non-MHC variants that could contribute to GVHD are minor histocompatibility antigens such as those encoded by the Y chromosome when female donors are used for male recipients, or minor antigens associated with common HLA alleles such as HLA-A*0201 [39]. Notably, the frequency of HLA-A*0201 and the proportion of gender-mismatched pairs were similar in the haplotype-matched and haplotype-mismatched groups; furthermore, gender mismatching was included in the regression models. Therefore, any contribution to GVHD from these minor antigens would not be expected to influence the impact of haplotype mismatching on GVHD risk in the study population. Finally, HLA-B and -C determinants are known to serve as ligands for natural killer (NK) cell receptors [40]. Since all study pairs were HLA-B and -C allele matched, and since the distributions of NK ligands in the haplotype-matched and haplotype-mismatched groups were similar (unpublished data), NK ligands cannot explain our findings.
###end p 56
###begin p 57
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
###xml 1200 1208 <span type="species:ncbi:9606">patients</span>
Mortality after HCT may be caused by transplant-related complications or by recurrent malignancy. The lack of a statistically significant association of MHC haplotype matching with overall survival was unexpected but may reflect the association of haplotype mismatching predominantly with clinically severe (grade III) GVHD rather than lethal (grade IV) GVHD. Even if the use of HLA-matched haplotype-matched unrelated donors does not improve overall survival, the effort to avoid or decrease the frequency of severe acute GVHD could provide clinical benefit. Donor-recipient haplotype matching may provide a novel strategy to decrease morbidity from GVHD and may be especially useful for patients who, because of medical reasons or advanced age, would not tolerate severe GVHD due to organ toxicity or prolonged immunosuppressive therapy. The patients in this study received T-replete unrelated donor grafts. Whether haplotype matching can further reduce GVHD risk after T cell-depleted transplantation remains to be determined. Further studies are warranted to define potential differences in the risk of mortality associated with grade III acute GVHD in haplotype-matched and haplotype-mismatched patients and to determine whether haplotype mismatching is associated with adverse outcomes after HCT with other preparative regimens, sources of stem cells, and immunosuppressive regimens.
###end p 57
###begin p 58
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b041">41</xref>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
Among haplotype-mismatched recipients, the increased risk of GVHD was offset by a lower risk of recurrent malignancy. Whether the lower risk of recurrent malignancy among haplotype-mismatched patients can be attributed to an increased risk of GVHD (through graft-versus-leukemia effects) or to causes that do not involve GVHD remains to be addressed in a larger transplant population [41]. At present, additional pharmacologic or immunotherapeutic strategies may be necessary in order to optimize overall transplant outcome if haplotype-matched donors are selected as a way of decreasing morbidity and mortality from GVHD in patients at high risk of recurrent malignancy after HCT.
###end p 58
###begin p 59
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b013">13</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b016">16</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b019">19</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b022">22</xref>
###xml 948 956 <span type="species:ncbi:9606">patients</span>
###xml 1019 1027 <span type="species:ncbi:9606">patients</span>
###xml 1133 1141 <span type="species:ncbi:9606">patients</span>
###xml 1328 1336 <span type="species:ncbi:9606">patients</span>
The determinants that contribute to GVHD risk after haplotype-mismatched transplantation could be located anywhere within the gene-rich MHC, and the effects could arise from either disparity between the donor and recipient haplotype-linked variation or from the direct effects of the variation itself. Previous studies have delineated the sequence of several well-known common HLA haplotypes [13,16,19-22]. Haplotypes that share the same alleles at a given HLA locus also share highly conserved segments or blocks of sequences in strong LD with the HLA allele. Thus, the degree of similarity between haplotype-mismatched combinations could vary considerably, and certain regions within the MHC may contribute different levels of GVHD risk associated with haplotype mismatching. If common haplotypes are more highly conserved for undetected variation in certain regions of the MHC than others, then the effect of haplotype mismatching on GVHD among patients with common haplotypes might be greater than the effect among patients with no common haplotypes, as suggested by our current results. If future studies with larger numbers of patients validate this hypothesis, the results would suggest that efforts to identify haplotype-matched donors would provide the greatest level of protection against GVHD in the subpopulation of patients with two common haplotypes.
###end p 59
###begin p 60
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 470 475 470 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 485 490 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 494 502 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 579 584 579 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 673 678 673 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 682 687 682 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-C</italic>
###xml 727 735 727 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 739 747 739 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 875 880 875 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-C</italic>
###xml 885 893 885 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b014">14</xref>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b016">16</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b017">17</xref>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b019">19</xref>
###xml 1091 1093 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b042">42</xref>
###xml 1430 1432 1430 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b014">14</xref>
###xml 1433 1435 1433 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b019">19</xref>
###xml 1436 1438 1436 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b026">26</xref>
###xml 1439 1441 1439 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b042">42</xref>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
###xml 1181 1189 <span type="species:ncbi:9606">patients</span>
An important question is whether transplant outcomes can be improved by matching for selected regions of HLA haplotypes that contribute the highest risk of GVHD. Additional technology will be needed to allow all haplotype-associated MHC genes to be tested for their individual contributions to GVHD risk, and a very large cohort will be needed to answer this question. At present, the similarity of GVHD probabilities in patients whose haplotypes differed from HLA-B to HLA-A and from HLA-B to HLA-DRB1 suggests that GVHD-risk genes are located both telomeric and centromeric to HLA-B. Furthermore, among the 191 haplotype-matched pairs, only four differed in linkage from HLA-B to HLA-C, and no cases differed in linkage from HLA-DRB1 to HLA-DQB1 (unpublished data). These results suggest that nearly all haplotype-matched pairs had identical five-locus haplotypes and that HLA-C and HLA-DQB1 provide additional markers for narrowing the potential regions of interest. Candidates include any gene-encoding polymorphic determinants that can function as transplantation antigens [14,16,17,19,42]. If only a few genes contribute to the increased risk of GVHD in haplotype-mismatched patients, refinement of our haplotyping method to include informative MHC class I, II, and III markers could be used to narrow the boundaries of GVHD-risk regions, allowing smaller regions to be examined at a higher level of genomic discrimination [14,19,26,42].
###end p 60
###begin p 61
###xml 237 245 <span type="species:ncbi:9606">patients</span>
Specific regions of mismatching between the donor and recipient MHC haplotypes might also have different effects on the risk of recurrent malignancy. In the current study, the limited numbers of class I and class II haplotype-mismatched patients precluded any informative analysis of the association of recurrent malignancy with class I versus class II haplotype mismatching. Information from future studies showing differences in the risk of recurrent malignancy associated with haplotype mismatching for specific MHC regions could facilitate development of an immunogenetic approach toward decreasing the risk of acute GVHD while preserving graft-versus-leukemia effects.
###end p 61
###begin p 62
###xml 148 164 148 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
Regardless of the number, nature, and location of GVHD-risk genes within the MHC, the results of the current study demonstrate that the three-locus HLA-A, -B, -DRB1 haplotype can serve as a proxy for GVHD risk. The ease of our haplotyping technique focused on only three genetic markers could provide clinicians with a simple tool for GVHD risk assessment and a means to decrease GVHD-associated morbidity after unrelated HCT. In the future, more refined mapping of GVHD-risk determinants will provide important information as to whether matching for certain regions of haplotypes will be clinically important.
###end p 62
###begin p 63
###xml 520 527 520 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040008-t002">Table 2</xref>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 559 571 <span type="species:ncbi:9606">participants</span>
Currently, patients with common HLA alleles in strong LD have the highest chances of identifying HLA allele-matched donors. We were interested in addressing whether the presence of common haplotypes in a recipient could be used as a predictor of haplotype matching, since this information has practical implications in the search for unrelated donors. Among the entire study population, the rate of haplotype matching was 78% for patients with two common haplotypes, 80% for those with one, and 71% for those with none (Table 2). Although the number of study participants was limited, these data suggest that allele frequency is only one parameter of successful donor haplotype matching.
###end p 63
###begin p 64
###xml 320 336 320 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
###xml 506 522 506 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b043">43</xref>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b044">44</xref>
###xml 133 140 <span type="species:ncbi:9606">patient</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 356 363 <span type="species:ncbi:9606">patient</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 542 549 <span type="species:ncbi:9606">patient</span>
###xml 555 562 <span type="species:ncbi:9606">patient</span>
###xml 596 603 <span type="species:ncbi:9606">patient</span>
###xml 709 717 <span type="species:ncbi:9606">patients</span>
Strong positive LD between low-frequency alleles increases the chance that a haplotype-matched donor might be identified for a given patient. For the 55 haplotype-mismatched patients in our study, a repeated search of the Bone Marrow Donors Worldwide database () identified between four and 1,777 (median: 65) potential HLA-A, -B, -DRB1-matched donors per patient. For the 45 patients of Northern European descent with two uncommon haplotypes, a repeated search identified up to 321 (median: 14) potential HLA-A, -B, -DRB1-matched donors per patient. One patient had a single donor, and only one patient had no other potential donors. These observations suggest that most five-locus-matched Northern European patients have several potential donors who could be prospectively haplotyped. Development of strategies to maximize the identification of potential haplotype-matched donors among the 10 million volunteer donors worldwide (; ) and to direct donor recruitment efforts in a way that provides optimal size and composition of registries ([43,44]; ) will be important research questions for the future.
###end p 64
###begin p 65
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b027">27</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b023">23</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b025">25</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b045">45</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b047">47</xref>
###xml 1024 1029 <span type="species:ncbi:9606">human</span>
Haplotypes have very high utility in hypothesis-driven and exploratory gene mapping. Our method for long-range haplotype definition could be used to assess the clinical importance of haplotypes in solid organ transplantation [27] and to discover genes that predispose to autoimmunity, infection, and cancer [23,25,45-47]. This method offers the potential for disease-association mapping without the need for individual tagSNP selection. Previous studies have been confounded by strong LD, which makes it difficult to determine whether disease susceptibility is conferred by the marker gene itself or by another gene in LD with the marker gene. Our haplotyping method will not surmount the problem of strongly linked genes, but it could be used to clarify physical linkages that differ between cases and controls and permit the measurement of independent effects. The ability to isolate high-quality intact genomic DNA for extended haplotyping provides an approach for screening causative variants even if the full extent of human haplotype diversity and structure are yet to be uncovered.
###end p 65
###begin title 66
Supporting Information
###end title 66
###begin title 67
Translation of the Abstract into German by H. J. Deeg
###end title 67
###begin p 68
(21 KB DOC)
###end p 68
###begin p 69
Click here for additional data file.
###end p 69
###begin title 70
Translation of the Abstract into French by L. Loubiere
###end title 70
###begin p 71
(25 KB DOC)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin title 73
Translation of the Abstract into Spanish by J. C. Pizarro
###end title 73
###begin p 74
(25 KB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin title 76
Translation of the Abstract into Chinese by H. Wang
###end title 76
###begin p 77
(21 KB DOC)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin title 79
Translation of the Abstract into Japanese by N. Fujii
###end title 79
###begin p 80
Found at doi: 27 KB DOC).
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin title 82
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
HLA-A, -B, -DRB1 Haplotypes in the Study Population
###end title 82
###begin p 83
(396 KB DOC)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin title 85
Accession Numbers
###end title 85
###begin p 86
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 51 72 51 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-B, -C, -DRB1, -DQB1,</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DPB1</italic>
The Entrez database () gene identifiers for HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 are 3105, 3106, 3107, 3123, 3119, and 3115, respectively.
###end p 86
###begin p 87
We thank Sharie Cheng, Michelle Baillie, and Mark Gatterman for technical assistance, and Dr. John Hansen and Eric Mickelson for providing cell lines.
###end p 87
###begin title 88
Abbreviations
###end title 88
###begin p 89
confidence interval
###end p 89
###begin p 90
graft-versus-host disease
###end p 90
###begin p 91
hematopoietic cell transplantation
###end p 91
###begin p 92
###xml 0 5 <span type="species:ncbi:9606">human</span>
human leukocyte antigen
###end p 92
###begin p 93
hazard ratio
###end p 93
###begin p 94
linkage disequilibrium
###end p 94
###begin p 95
major histocompatibility complex
###end p 95
###begin p 96
natural killer
###end p 96
###begin p 97
odds ratio
###end p 97
###begin p 98
single nucleotide polymorphism
###end p 98
###begin title 99
References
###end title 99
###begin article-title 100
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome
###end article-title 100
###begin article-title 101
###xml 30 35 <span type="species:ncbi:9606">human</span>
Linkage disequilibrium in the human genome
###end article-title 101
###begin article-title 102
Prospects for whole-genome linkage disequilibrium mapping of common disease genes
###end article-title 102
###begin article-title 103
###xml 23 28 <span type="species:ncbi:9606">human</span>
A haplotype map of the human genome
###end article-title 103
###begin article-title 104
###xml 38 43 <span type="species:ncbi:9606">human</span>
Complete sequence and gene map of the human major histocompatibility complex
###end article-title 104
###begin article-title 105
Islands of linkage disequilibrium
###end article-title 105
###begin article-title 106
Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population
###end article-title 106
###begin article-title 107
A comparison of bayesian methods for haplotype reconstruction from population genotype data
###end article-title 107
###begin article-title 108
Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type
###end article-title 108
###begin article-title 109
Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
###end article-title 109
###begin article-title 110
Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism
###end article-title 110
###begin article-title 111
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
###end article-title 111
###begin article-title 112
###xml 51 56 <span type="species:ncbi:9606">human</span>
Inheritable variable sizes of DNA stretches in the human MHC: Conserved extended haplotypes and their fragments or blocks
###end article-title 112
###begin article-title 113
###xml 52 57 <span type="species:ncbi:9606">human</span>
A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms
###end article-title 113
###begin article-title 114
MHC microsatellite diversity and linkage disequilibrium among common HLA-A, HLA-B, DRB1 haplotypes: Implications for unrelated donor hematopoietic transplantation and disease association studies
###end article-title 114
###begin article-title 115
Complete MHC haplotype sequencing for common disease gene mapping
###end article-title 115
###begin article-title 116
###xml 35 40 <span type="species:ncbi:9606">human</span>
An integrated haplotype map of the human major histocompatibility complex
###end article-title 116
###begin article-title 117
Ancestral haplotypes: Conserved population MHC haplotypes
###end article-title 117
###begin article-title 118
###xml 118 123 <span type="species:ncbi:9606">human</span>
Genetic analysis of completely sequenced disease-associated MHC haplotypes identifies shuffling of segments in recent human history
###end article-title 118
###begin article-title 119
###xml 88 93 <span type="species:ncbi:9606">human</span>
Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC
###end article-title 119
###begin article-title 120
Multi-SNP analysis of MHC region: Remarkable conservation of HLA-A1-B8-DR3 haplotype
###end article-title 120
###begin article-title 121
The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases
###end article-title 121
###begin article-title 122
An update of the HLA genomic region, locus information and disease associations: 2004
###end article-title 122
###begin article-title 123
Reconstruction of the block matching profiles
###end article-title 123
###begin article-title 124
Panning for gold: Genome-wide scanning for linkage in type 1 diabetes
###end article-title 124
###begin article-title 125
The MHC haplotype project: A resource for HLA-linked association studies
###end article-title 125
###begin article-title 126
Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation
###end article-title 126
###begin article-title 127
Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program
###end article-title 127
###begin article-title 128
Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome
###end article-title 128
###begin article-title 129
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation
###end article-title 129
###begin article-title 130
Duration of immunosuppressive treatment for chronic graft-versus-host disease
###end article-title 130
###begin article-title 131
Long-range multilocus haplotype phasing of the MHC
###end article-title 131
###begin article-title 132
Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
###end article-title 132
###begin article-title 133
Limits of HLA mismatching in unrelated hematopoietic cell transplantation
###end article-title 133
###begin article-title 134
The accuracy of statistical methods for estimation of haplotype frequencies: An example from the CD4 locus
###end article-title 134
###begin article-title 135
Direct molecular haplotyping of long-range genomic DNA with M1-PCR
###end article-title 135
###begin article-title 136
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma
###end article-title 136
###begin article-title 137
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation
###end article-title 137
###begin article-title 138
Minor histocompatibility antigens
###end article-title 138
###begin article-title 139
Natural killer cell receptors: Regulating innate immune responses to hematologic malignancy
###end article-title 139
###begin article-title 140
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
###end article-title 140
###begin article-title 141
###xml 25 30 <span type="species:ncbi:9606">human</span>
Gene map of the extended human MHC
###end article-title 141
###begin article-title 142
Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors
###end article-title 142
###begin article-title 143
HLA gene haplotype frequencies in bone marrow donors worldwide registries
###end article-title 143
###begin article-title 144
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease
###end article-title 144
###begin article-title 145
###xml 8 13 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
###end article-title 145
###begin article-title 146
A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility
###end article-title 146
###begin title 147
Figures and Tables
###end title 147
###begin title 148
###xml 26 36 26 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B,</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
Long-Range Haplotyping of HLA-A, -B, and -DRB1 in Unrelated Individuals
###end title 148
###begin p 149
###xml 119 129 119 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B,</italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-DRB1</italic>
(A) Schematic illustration of two HLA phenotypically identical individuals with the same or different linkages between HLA-A, -B, and -DRB1 on the MHC haplotypes.
###end p 149
###begin p 150
###xml 172 178 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A,</italic>
###xml 192 201 192 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1,</italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1,</italic>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 497 505 497 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 575 580 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 588 596 588 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b032">32</xref>
###xml 999 1004 999 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 1058 1063 1058 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 1077 1082 1077 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 1088 1092 1088 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 1155 1157 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040008-b032">32</xref>
(B) DNA microarray images of four unrelated donor-recipient pairs from the study population demonstrating MHC haplotype-matched (upper left), and MHC haplotype-mismatched (HLA-A, upper right; HLA-DRB1, lower left; HLA-A and -DRB1, lower right) relationships. The two haplotypes in each sample were separated by hybridizing genomic DNA to an array that was spotted with oligonucleotide probes, each specific for one of the two HLA-B alleles in the sample. After haplotype separation, the HLA-A and HLA-DRB1 alleles carried on each haplotype were identified with the use of 57 HLA-A and 64 HLA-DRB1 oligonucleotide probes as described [32]. Actual quadruplicate hybridization patterns for 16 of the probes illustrate how the two possible alleles at each locus could be distinguished from each other. Each column of panels in the figure shows the pattern of probe hybridization with one of the two MHC haplotypes from each sample. Allele assignments are indicated above each hybridization pattern. The HLA-B probe hybridization patterns validate the linkage of HLA-B alleles with HLA-A and -DRB1 alleles. Sequences and specificity of probes can be found in [32].
###end p 150
###begin title 151
Clinical Outcome after Haplotype-Matched (Solid Line) and Haplotype-Mismatched (Broken Line) Unrelated Donor HCT
###end title 151
###begin p 152
###xml 31 54 31 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, B, C, DRB1, DQB1</italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
All patients in the study were HLA-A, B, C, DRB1, DQB1 allele matched with their donors.
###end p 152
###begin p 153
(A) Probability of grades III-IV acute GVHD.
###end p 153
###begin p 154
(B) Probability of recurrent malignancy.
###end p 154
###begin p 155
(C) Probability of transplant-related mortality.
###end p 155
###begin p 156
(D) Probability of survival.
###end p 156
###begin p 157
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 80 87 <span type="species:ncbi:9606">patient</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
One patient in the mismatched group had recurrent malignancy at 14.4 y, and one patient in the mismatched group died without recurrent malignancy at 13.2 y. Seven mismatched patients are alive without recurrent malignancy from 11.9-14.1 y, and nine mismatched patients are alive from 11.0-14.5 y. Twenty-three patients in the matched group are alive without recurrent malignancy from 10.2-18.5 y, and 28 matched patients are alive from 10.2-18.5 y. Each of these patients is indicated as censored at 10 y in (B), (C), and (D).
###end p 157
###begin p 158
Characteristics of the Study Population
###end p 158
###begin p 159
###xml 53 69 53 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
Probability of Grades III-IV Acute GVHD According to HLA-A, -B, -DRB1 Haplotype Matching and Number of Common Haplotypes
###end p 159
###begin p 160
###xml 19 35 19 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A, -B, -DRB1</italic>
Adjusted Effect of HLA-A, -B, -DRB1 Haplotype Mismatching on Risks of Grades III-IV Acute GVHD, Recurrent Malignancy, Transplant-Related Mortality, and Mortality after HCT from HLA-Identical Unrelated Donors
###end p 160
###begin p 161
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. EWP contributed the study hypothesis and study design. ZG developed and carried out the haplotyping protocol, and MM managed the laboratory database. EWP, MM, and ZG analyzed haplotyping data, and PJM assisted in the analysis of GVHD. TAG performed the statistical analysis. All authors contributed to the preparation of the manuscript.
###end p 161
###begin p 162
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This work was supported by grants CA100019, CA18029, AI49213, and AI33484 from the US National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 162
###begin p 163
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: EWP and ZG have applied for a US non-provisional 111(a) patent for the haplotyping method, serial number 10/843,985. The remaining authors have no conflict of interest.
###end p 163

